PSMA-11 free base | CAS#1366302-52-4 | ligand to make gallium Ga 68-labeled PSMA-11

MedKoo Cat#: 556010 | Name: PSMA-11 free base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Gozetotide, also known as PSMA-11, DKFZ-PSMA-11, HBED-CC-PSMA or Psma-hbed-CC, is a ligand to make gallium Ga 68-labeled PSMA-11, which has potential use as a tracer for PSMA-expressing tumors during positron emission tomography (PET). Upon intravenous administration of gallium Ga 68-labeled PSMA-11, the Glu-urea-Lys(Ahx) moiety targets and binds to PSMA-expressing tumor cells. Upon internalization, PSMA-expressing tumor cells can be detected during PET imaging. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells

Chemical Structure

PSMA-11 free base

CAS#1366302-52-4 (free base)

Theoretical Analysis

MedKoo Cat#: 556010

Name: PSMA-11 free base

CAS#: 1366302-52-4 (free base)

Chemical Formula: C44H62N6O17

Exact Mass: 946.4171

Molecular Weight: 947.01

Elemental Analysis: C, 55.81; H, 6.60; N, 8.87; O, 28.72

Price and Availability

Size	Price	Availability
1mg	USD 150.00	2 Weeks
5mg	USD 450.00	2 Weeks
10mg	USD 750.00	2 Weeks
25mg	USD 1,650.00	2 Weeks
50mg	USD 2,950.00	2 Weeks
100mg	USD 5,250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

2412149-32-5 (TFA) 1366302-52-4 (free base) PSMA-11 HCl

Synonym

DKFZ-PSMA-11; Psma-hbed-CC; PSMA-11; PSMA11; PSMA 11; HBED-CC-PSMA; PSMA-11 TFA; Psma-hbed-CC; gozetotide;

IUPAC/Chemical Name

(3S,7S)-22-(3-(((2-((5-(2-Carboxyethyl)-2-hydroxybenzyl)(carboxymethyl)amino)ethyl)(carboxymethyl)amino)methyl)-4-hydroxyphenyl)-5,13,20-trioxo-4,6,12,19-tetraazadocosane-1,3,7-tricarboxylic acid

InChi Key

QJUIUFGOTBRHKP-LQJZCPKCSA-N

InChi Code

InChI=1S/C44H62N6O17/c51-34-13-8-28(22-30(34)24-49(26-40(59)60)20-21-50(27-41(61)62)25-31-23-29(9-14-35(31)52)11-16-38(55)56)10-15-37(54)46-18-4-1-2-7-36(53)45-19-5-3-6-32(42(63)64)47-44(67)48-33(43(65)66)12-17-39(57)58/h8-9,13-14,22-23,32-33,51-52H,1-7,10-12,15-21,24-27H2,(H,45,53)(H,46,54)(H,55,56)(H,57,58)(H,59,60)(H,61,62)(H,63,64)(H,65,66)(H2,47,48,67)/t32-,33-/m0/s1

SMILES Code

O=C(O)CC[C@H](NC(N[C@@H](CCCCNC(CCCCCNC(CCC1=CC=C(O)C(CN(CC(O)=O)CCN(CC2=CC(CCC(O)=O)=CC=C2O)CC(O)=O)=C1)=O)=O)C(O)=O)=O)C(O)=O

Appearance

Solid powder

Purity

>97% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#A22T02K18

QC Data

View QC data: current batch, Lot#A22T02K18

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

Ga 68 PSMA-11 binds to prostate-specific membrane antigen (PSMA). It binds to cells that express PSMA, including malignant prostate cancer cells, which usually overexpress PSMA. Gallium-68 (Ga 68) is a β+ emitting radionuclide that allows positron emission tomography (PET).

In vitro activity:

The procedure was completely automated and provided a high radiochemical yield. It can be performed several times a day, facilitating the clinical demand of this radiopharmaceutical. Reference: Reverchon J, Khayi F, Roger M, Moreau A, Kryza D. Optimization of the radiosynthesis of [68Ga]Ga-PSMA-11 using a Trasis MiniAiO synthesizer: do we need to heat and purify? Nucl Med Commun. 2020 Sep;41(9):977-985. doi: 10.1097/MNM.0000000000001233. PMID: 32796487.

In vivo activity:

A total of 635 men were enrolled with a median age of 69 years (range, 44-95 years). On a per-patient basis, PPV was 0.84 (95% CI, 0.75-0.90) by histopathologic validation (primary endpoint, n = 87) and 0.92 (95% CI, 0.88-0.95) by the composite reference standard (n = 217). 68Ga-PSMA-11 PET localized recurrent prostate cancer in 475 of 635 (75%) patients; detection rates significantly increased with prostate-specific antigen (PSA): 38% for <0.5 ng/mL (n = 136), 57% for 0.5 to <1.0 ng/mL (n = 79), 84% for 1.0 to <2.0 ng/mL (n = 89), 86% for 2.0 to <5.0 ng/mL (n = 158), and 97% for ≥5.0 ng/mL (n = 173, P < .001). Interreader reproducibility was substantial (Fleiss κ, 0.65-0.78). There were no serious adverse events associated with 68Ga-PSMA-11 administration. PET-directed focal therapy alone led to a PSA drop of 50% or more in 31 of 39 (80%) patients.Using blinded reads and independent lesion validation, high PPV for 68Ga-PSMA-11 PET, detection rate and interreader agreement for localization of recurrent prostate cancer. Reference: Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019 Jun 1;5(6):856-863. doi: 10.1001/jamaoncol.2019.0096. PMID: 30920593; PMCID: PMC6567829.

	Solvent	mg/mL	mM
Solubility
	DMSO	100.0	105.60

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 947.01 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

Reverchon J, Khayi F, Roger M, Moreau A, Kryza D. Optimization of the radiosynthesis of [68Ga]Ga-PSMA-11 using a Trasis MiniAiO synthesizer: do we need to heat and purify? Nucl Med Commun. 2020 Sep;41(9):977-985. doi: 10.1097/MNM.0000000000001233. PMID: 32796487.

In vitro protocol:

In vivo protocol:

Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019 Jun 1;5(6):856-863. doi: 10.1001/jamaoncol.2019.0096. PMID: 30920593; PMCID: PMC6567829.

1: Santo G, Santo GD, Sviridenko A, Bayerschmidt S, Wirth L, Scherbauer F, Lehmann P, von Guggenberg E, Decristoforo C, Heidegger-Pircher I, Bektic J, Virgolini I. Efficacy and safety of rechallenge with [177Lu]Lu- PSMA-I&T radioligand therapy in metastatic castration resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2024 Sep 3. doi: 10.1007/s00259-024-06905-5. Epub ahead of print. PMID: 39225826. 2: Sangiwa BA, Burger C, Ellmann A. Evaluation of Gallium-68 prostate-specific membrane antigen, positron emission tomography/computed tomography (GA-68 PSMA PET/CT) in recurrent prostate cancer: a retrospective review of initial clinical experience at Tygerberg Hospital. Pan Afr Med J. 2024 May 30;48:30. doi: 10.11604/pamj.2024.48.30.38084. PMID: 39220559; PMCID: PMC11364939. 3: Rahbar Nikoukar L, Seifert R, Ventura D, Schindler P, Bögemann M, Rahbar K, Roll W. Prognostic value of pretherapeutic 68Ga-PSMA-11-PET based imaging parameters in mCRPC patients treated with PSMA radioligands. Nuklearmedizin. 2024 Aug 29. English. doi: 10.1055/a-2383-2468. Epub ahead of print. PMID: 39209284. 4: Pabst KM, Mei R, Lückerath K, Hadaschik BA, Kesch C, Rawitzer J, Kessler L, Bodensieck LS, Hamacher R, Pomykala KL, Fanti S, Herrmann K, Fendler WP. Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [68Ga]Ga-/[18F]F-PSMA-11/-1007, [68Ga]Ga- FAPI-46 and 2-[18F]FDG PET/CT: a pilot study. Eur J Nucl Med Mol Imaging. 2024 Aug 29. doi: 10.1007/s00259-024-06891-8. Epub ahead of print. PMID: 39207485. 5: Da Ros V, Filippi L, Garaci F. Intra-arterial administration of PSMA-targeted radiopharmaceuticals for brain tumors: is the era of interventional theranostics next? Expert Rev Anticancer Ther. 2024 Aug 29:1-5. doi: 10.1080/14737140.2024.2398492. Epub ahead of print. PMID: 39206859. 6: Ghaedian T, Alipour A, Rakhsha A, Nasrollahi H, Saffarian A. Early Impact of Bevacizumab on the 99m Tc-HYNIC-PSMA-11 Uptake in a Case of Recurrent Glioblastoma Multiforme. Clin Nucl Med. 2024 Oct 1;49(10):e528-e529. doi: 10.1097/RLU.0000000000005435. PMID: 39192507. 7: Thin P, Hotta M, Gafita A, Grogan T, Czernin J, Calais J, Sonni I. Clinical Factors That Influence Repeat 68Ga-PSMA-11 PET/CT Scan Positivity in Patients with Recurrent Prostate Cancer Under Observation After a Negative 68Ga-PSMA-11 PET/CT Scan: A Single-Center Retrospective Study. J Nucl Med. 2024 Aug 21:jnumed.124.267591. doi: 10.2967/jnumed.124.267591. Epub ahead of print. PMID: 39168522. 8: Sundset R, Haugnes HS, Perez A, Engelsen O, Fosseide IHH, Castillejo MJ, Bogsrud TV. ¹⁷⁷Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. Tidsskr Nor Laegeforen. 2024 Jul 30;144(9). English, Norwegian. doi: 10.4045/tidsskr.23.0478. PMID: 39166985. 9: Kuo PH, Morris MJ, Hesterman J, Kendi AT, Rahbar K, Wei XX, Fang B, Adra N, Garje R, Michalski JM, Chi K, de Bono J, Fizazi K, Krause B, Sartor O, Tagawa ST, Ghebremariam S, Brackman M, Wong CC, Catafau AM, Benson T, Armstrong AJ, Herrmann K. Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu- PSMA-617 (VISION Trial). Radiology. 2024 Aug;312(2):e233460. doi: 10.1148/radiol.233460. PMID: 39162634; PMCID: PMC11366674. 10: Usmani S, Riyami KA, Numani SP, Hashmi SF, Jain A, Sukaiti RA, Ahmed N, Shamim MS. Molecular imaging with 68Ga-PSMA PET/CT in high grade glioma: A biomarker for tumour neo-angiogenesis. J Pak Med Assoc. 2024 Aug;74(8):1552-1554. doi: 10.47391/JPMA.24-64. PMID: 39160736. 11: Kohlbrenner R, Wu X, Nguyen HG, Cooperberg MR, Chakravarty T, Carroll PR, Hope TA. Pharmacokinetic Comparison of Selective Prostatic Arterial and Intravenous PSMA PET/CT Radioligand Infusions in Primary Prostatic Adenocarcinoma. Radiology. 2024 Aug;312(2):e232544. doi: 10.1148/radiol.232544. PMID: 39136560; PMCID: PMC11366670. 12: Cieślewicz M, Andryszak N, Pełka K, Szczepanek-Parulska E, Ruchała M, Kunikowska J, Czepczyński R. Parathyroid Adenoma Detected in 68Ga- PSMA PET/CT but Not in the Dedicated Imaging Modalities. Diagnostics (Basel). 2024 Aug 5;14(15):1690. doi: 10.3390/diagnostics14151690. PMID: 39125566; PMCID: PMC11312185. 13: Hein C, Burgard C, Blickle A, Bastian MB, Maus S, Schaefer-Schuler A, Hoffmann MA, Schreckenberger M, Ezziddin S, Rosar F. Analysis of Molecular Imaging and Laboratory Baseline Biomarkers in PSMA-RLT: Whole-Body Total Lesion PSMA (TLP) Predicts Overall Survival. Cancers (Basel). 2024 Jul 26;16(15):2670. doi: 10.3390/cancers16152670. PMID: 39123398; PMCID: PMC11311702. 14: Mainta IC, Neroladaki A, Wolf NB, Benamran D, Boudabbous S, Zilli T, Garibotto V. [68Ga]Ga-PSMA-11 PET and Prostate Cancer Bone Metastases: Diagnostic Performance of Available Standardized Criteria. J Nucl Med. 2024 Sep 3;65(9):1376-1382. doi: 10.2967/jnumed.124.267899. PMID: 39117453. 15: Gülbahar Ateş S, Demirel BB, Kekilli E, Öztürk E, Uçmak G. Primary tumor heterogeneity on pre-treatment [68Ga]Ga-PSMA PET/CT for the prediction of biochemical recurrence in prostate cancer. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2024 Aug 2:500032. doi: 10.1016/j.remnie.2024.500032. Epub ahead of print. PMID: 39097169. 16: Dell'Oro M, Huff DT, Lokre O, Kendrick J, Munian Govindan R, Ong JSL, Ebert MA, Perk TG, Francis RJ. Assessing the Heterogeneity of Response of [68Ga] Ga-PSMA-11 PET/CT Lesions in Patients With Biochemical Recurrence of Prostate Cancer. Clin Genitourin Cancer. 2024 Jul 6;22(5):102155. doi: 10.1016/j.clgc.2024.102155. Epub ahead of print. PMID: 39096564. 17: Veenstra MMK, Vegt E, Segbers M, Franssen S, Koerkamp BG, Verburg FA, Thomeer MGJ. Intra-arterial PSMA injection using hepatic arterial infusion pump in intrahepatic cholangiocarcinoma: a proof-of-concept study. Eur Radiol Exp. 2024 Aug 1;8(1):90. doi: 10.1186/s41747-024-00496-4. PMID: 39090480; PMCID: PMC11294287. 18: Li S, Nguyen A, Counter W, John NC, De Leon J, Hruby G, Joshua AM, Stricker P, Crumbaker M, Ayati N, Chan L, Sabahi Z, Swiha M, Kneebone A, Wong K, Liu V, Sharma S, Agrawal S, Emmett LM. Utility of 64Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on 68Ga-PSMA-11 PET/CT. J Nucl Med. 2024 Sep 3;65(9):1371-1375. doi: 10.2967/jnumed.124.267881. PMID: 39089814. 19: Rupp NJ, Freiberger SN, Ferraro DA, Laudicella R, Heimer J, Muehlematter UJ, Poyet C, Moch H, Eberli D, Rüschoff JH, Burger IA. Immunohistochemical ERG positivity is associated with decreased PSMA expression and lower visibility in corresponding [68Ga]Ga-PSMA-11 PET scans of primary prostate cancer. Eur J Nucl Med Mol Imaging. 2024 Jul 31. doi: 10.1007/s00259-024-06856-x. Epub ahead of print. PMID: 39083067. 20: Henríquez I, Malave B, Campos FL, Hidalgo EC, Muelas R, Ferrer C, Muñoz- Rodriguez J, Villamón AM, Pascual MC, Badia J, Fuertes J, Hinojosa-Salas P. PSMA PET/CT SUVmax as a prognostic biomarker in patients with metachronous metastatic hormone-sensitive prostate cancer (mHSPC). Clin Transl Oncol. 2024 Jul 29. doi: 10.1007/s12094-024-03625-y. Epub ahead of print. PMID: 39073734.